The measurement of Gankyrin expression, combined with carcinoembryonic antigen (CEA) detection and other clinical indicators, is expected to improve the individual evaluation and management of CRC patients at a high risk of occult liver metastasis. This evidence concerns the gene PSMD10 and metastasis.